Company: INDP
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001641172-25-023333
Chunk: 33

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 1
Chunk 33
---

  
    Additional paid in capital* 
     68,521,126  
     64,379,770 
  
    Accumulated deficit 
     (70,200,532) 
     (60,439,183)

    Total stockholders’ equity (deficit) 
     (1,673,356) 
     3,944,875 

    Total liabilities and stockholders’ equity (deficit) 
    $6,839,207  
    $7,338,756 

*Retroactively
                                                                                                                                                                                        restated for one-for-twenty-eight share consolidation on June 27, 2025.

See
accompanying notes to the unaudited condensed consolidated financial statements

F-1

INDAPTUS
THERAPEUTICS, INC.

Unaudited
Condensed Consolidated Statements of Operations

    2025  
    2024  
    2025  
    2024 

    Three Months Ended June 30,  
    Six Months Ended June 30, 

    2025  
    2024  
    2025  
    2024 
  
    Operating expenses: 

    Research and development 
    $2,167,114  
    $1,713,973  
    $4,977,954  
    $3,305,115 
  
    General and administrative 
     2,289,649  
     2,394,912  
     4,051,368  
     4,747,009 

    Total operating expenses 
     4,456,763  
     4,108,885  
     9,029,322  
     8,052,124 

    Loss from operations 
     (4,456,763) 
     (4,108,885) 
     (9,029,322) 
     (8,052,124)

    Other income, net 
     15,547  
     93,618  
     55,676  
     230,180 
  
     Change in fair value of convertible promissory notes 
     (787,703) 
     -  
     (787,703) 
     - 

    Net loss 
    $(5,228,919) 
    $(4,015,